Ikena therapeutics

Author: nrbp

August undefined, 2024

WebBackground. NTRK fusions are actionable biomarkers with efficient and well tolerated TRKis. Clinical profile and outcomes of pts with NTRK+ tumours receiving non-TRKi SoC are unknown and the prognosis of NTRK+ pts vs pts with NTRK fusion-negative (NTRK–) tumours is not well known. WebCedilla’s conditional inhibitors are small molecules that are unlocking historically undruggable cancer targets for therapeutic development. Our asset-by-asset approach is not one-size-fits-all. We start by developing a deep understanding of the disease biology and contextual biochemistry of the target. We then deploy cutting-edge ...

Grapiprant and Pembrolizumab in Patients With Advanced or …

WebKyn Therapeutics is advancing development programs with targets strongly implicated in immunosuppression across a range of tumor types and via multiple immune cell effects. … WebOur Pipeline. As we evolve with our science, our multifaceted approach builds a robust pipeline of patient direct therapies. At Ikena™, we are advancing a portfolio of targeted … dr jayaraj joplin mo

Three Biopharma Companies Making Their Nasdaq Debut

Web17 dec. 2024 · The new name, “Ikena,” is derived from the combination of “i” which refers to the individual patient and “ken” which means knowledge, thereby illustrating our focus on … Web7 mrt. 2024 · Ikena is advancing IK-930 both as a monotherapy in patients with Hippo pathway mutated cancers and in combination with other approved targeted therapies to … WebLearn about the team at Repare Therapeutics, a clinical-stage precision oncology company discovering and developing novel, synthetic lethal ... . Christopher’s Hospital in Philadelphia. Dr. Koehler serves as an independent director on the boards of directors of Ikena Therapeutics and Silverback Therapeutics. Dr. Koehler is a board-certified ... ra.mi srl

Kyn Therapeutics Rebrands as Ikena Oncology, Reflecting Next …

Ikena Oncology Biomarker-Driven Cancer Therapeutics

Web14 mrt. 2024 · Ikena Oncology : Corporate Presentation - March 2024. We develop differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco- signaling network. Ikena Wholly Owned Pipeline Focused on Targeted Oncology in Hippo-Ras Oncosignaling Network. Web7 okt. 2024 · Pioneering treatments for neurodegenerative diseases. Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases. Our founders’ groundbreaking discoveries in RNA interference offer a powerful therapeutic approach to halt diseases at their source. Atalanta's. branched siRNA. dr jayaraj jackson msWeb5 sep. 2024 · Arrys Therapeutics: ClinicalTrials.gov Identifier: NCT03658772 Other Study ID Numbers: ARYS-001 Keynote-878 ( Other Identifier: Merck Sharp & Dohme Corp. ) First Posted: September 5, 2024 Key Record Dates: Last Update Posted: April 22, 2024 Last Verified: April 2024 dr. jaya r. trivedi md

"Web28 nov. 2024 · Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, announced that management will participate in a … " - Ikena therapeutics

Ikena therapeutics

Kyn to Ikena: The Art and Science of Rebranding - LifeSciVC

Web28 nov. 2024 · Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance. 10/26/2024. Ikena Oncology, Inc. today announced a poster presentation highlighting preclinical data on the company’s novel TEAD inhibitor, IK-930, at the 34th EORTC-NCI … Web26 mrt. 2024 · Noam Galai/Getty Images. This week began with four biopharma companies announcing intentions to become publicly traded companies and it’s ending with three companies making their debut on the Nasdaq. This morning, two of those companies, Ikena Oncology and Design Therapeutics, join Edgewise Therapeutics by trading on the …

Did you know?

Web7 mrt. 2024 · Dr. Jeff Ecsedy, Ikena’s Chief Development Officer, will present data supporting the potential of IK-930 as a clinical agent during a minisymposium on experimental and molecular cancer therapeutics. WebIkena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is …

Web2 nov. 2024 · Ikena is developing IK-930 as a potential targeted therapy for patients with cancers that exhibit genetic alterations across the Hippo pathway. IK-930 is designed to selectively bind TEAD and to disrupt TEAD-dependent transcription of key genes involved in cancer progression, metastases, and therapeutic resistance. WebFounded Date 2014. Founders Sofie Qiao. Operating Status Active. Last Funding Type Series C. Legal Name Vivace Therapeutics, Inc. Company Type For Profit. Contact Email [email protected]. Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel …

WebIkena Oncology (formerly Kyn Therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed therapies for cancer patients, by understanding … WebPatient-directed oncology therapies across pathways relevant in tumor and immune cells Ikena is a targeted oncology company focused on developing novel cancer therapies …

Web26 mrt. 2024 · Ikena Oncology, a company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, begins …

Web24 mrt. 2024 · Ikena Oncology (formerly Kyn Therapeutics) is a biotechnology company that discovers and develops biomarker-driven therapies for cancer treatment. ... Ikena Oncology Financials. Summary financials. Revenue (Q3, 2024)$6.4M Net income (Q3, 2024)($17.3M) Cash (FY, 2024)$59.9M EBIT (Q3, 2024) ramistan drugWebIkena is redefining the targeted oncology landscape and envisioning a world in which every cancer patient has a cure, guided by a deep understanding of the patient experience and … dr jay arora azWebDescription. Developer of an immuno-metabolism therapy technology designed to translate high-impact science into medicines for patients. The company's technology is meant for implementation in human clinical studies for non-oncology indications, enabling doctors to treat cancer patients in a better and hassle-free way. dr jayaraj s pWeb5 jan. 2024 · Their stock opened with $16.00 in its Mar 26, 2024 IPO. Ikena Oncology is funded by 12 investors. Bristol Myers Squibb and Cowen Healthcare Investments are the most recent investors. Ikena Oncology has a post-money valuation in the range of $500M to $1B as of Jan 6, 2024, according to PrivCo. Sign up for a free trial to view exact … dr jayashree srinivasanWeb2 nov. 2024 · Preclinical research, including data presented by Ikena at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2024, suggests that IK-930 is a ... ramita navai podcast ramita ordinacijaWebIkena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product … dr. jayaraj tx